Active — Not RecruitingPhase 2/3

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

United States127 participantsStarted 2022-01-15

Plain-language summary

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line) * Adequate Bone Marrow Function. * Adequate Renal \& Liver Function. * Adequate Performance Status Exclusion Criteria: * Patients with known symptomatic central nervous system (CNS) metastases or leptomeningeal disease requiring steroids. * Prior treatment with any anti-CD47 or anti-SIRPα agent. * Prior treatment with ramucirumab.

What they're measuring

Phase 2

Timeframe: Last randomized patient on study at least 16 weeks

Phase 3

Timeframe: From the date of randomization to the date of death (due to any cause), up to 36 months postdose

Trial details

NCT IDNCT05002127

SponsorALX Oncology Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-05-24

View on ClinicalTrials.gov More Gastric Cancer trials